Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis

 
• By Jessica Merrill

The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.

uncertainty
Investors weren't sure what to make of Phase II data from Protagonist • Source: Alamy

More from Clinical Trials

More from R&D